A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft- versus -host disease: BMT CTN 0801

Authors:

Abstract
Initial therapy of chronic graft-versus-host disease is prednisone ± calcineurin-inhibitor, but most patients respond inadequately. In a randomized, adaptive phase 2/3 multicenter trial we studied whether prednisone/sirolimus or prednisone/sirolimus/photopheresis was more effective than prednisone/sirolimus/calcineurin-inhibitor for treating chronic graft-versus-host disease in treatment-naive or early inadequate responders. Primary endpoints were proportions of subjects alive without relapse or secondary therapy with 6-month complete or partial response in phase-2, or with 2-year complete response in phase-3. The prednisone/sirolimus/photopheresis-arm closed prematurely due to slow accrual and the remaining 2-drug vs. 3-drug study ended in phase-2 for statistical futility with 138 evaluable subjects. The 2-drug and 3-drug arms did not differ in rates of 6-month complete or partial response (48.6% vs 50.0%, P = .87), or 2-year complete responses (14.7% vs 15.5%, P = .90). Serum creatinine >1.5 times baseline was less frequent on the calcineurin-inhibitor-free arm at 2 and 6 months (1.5% vs 11.7%, P = .025; 7.8% vs 24.0%, P = .016). Higher adjusted Short Form-36 Physical Component Summary and Physical Functioning scores were seen on the 2-drug arm at 2 and 6 months (P = .02 and .04; P = .007 and .001). Failure-free survival and overall survival at 2 years were similar for the 2-drug and 3-drug arms (48.6% vs 46.2%, P = .78; 81.5% vs 74%, P = .28). Based on similar long-term outcomes, prednisone/sirolimus is a therapeutic alternative to prednisone/sirolimus/calcineurin-inhibitor for chronic graft-versus-host disease that is easier to administer and better tolerated. This study was registered at http://www.clinicaltrials.gov (NCT01106833).

This publication has 31 references indexed in Scilit: